EMA Tightens Rules on “Revolving Door” for Committee Members and Experts
The European Medicines Agency (EMA) has updated its rules on declarations of interests for scientific committee members and experts. The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The updates also include a revised guide on how to complete the Agency’s declaration of interest form.
EMA’s declaration of interest policy aims for a balanced approach by effectively restricting the involvement of experts with possible conflicts of interests in the Agency’s work while maintaining EMA’s ability to access the best available expertise.
“The effective management of conflicts of interests is key to ensuring the independence and integrity of the Agency’s scientific recommendations,” says Noël Wathion, EMA’s Chief Policy Adviser. “EMA continually reviews its policy to ensure that the rules are fit for purpose.”
EMA considers that employment in a pharmaceutical company is incompatible with an involvement in Agency activities. Whenever a member of a scientific committee or working party informs the Agency that he/she intends to work for a pharmaceutical company, the Agency will immediately restrict the member from any participation in the evaluation of medicines. If necessary, the Agency will also verify whether the integrity of any ongoing or past scientific reviews in which that person was involved could have been compromised. These rules are reflected in the updated policy and in a new guidance document.
EMA’s policy on handling declarations of interest
In March 2014, the EMA management board endorsed a major revision of EMA’s policy on handling declarations of interest for scientific committee members and experts. The revision took into account input from stakeholders at the Agency’s September 2013 public workshop 'Best expertise vs conflicts of interests: striking the right balance'. It entered into force on 30 January 2015. EMA will continue to review its policy on a regular basis. The current updates build on the Agency’s early experience with the revised policy.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
